文献速递预防保健、筛查与疫苗老年与多病共存

带状疱疹活疫苗在接种后10年内的有效性:基于电子健康记录的真实世界队列研究

Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records.
PubMed 文献 · BMJ · 2023-11-08

结果显示疫苗对带状疱疹的保护在接种第一年最高(67%),随后显著下降,10年后降至15%;对带状疱疹后神经痛的保护从83%降至41%,但仍有部分保护。

要点

  • 带状疱疹活疫苗对带状疱疹的保护第一年为67%,10年后降至15%。
  • 对带状疱疹后神经痛的保护第一年为83%,10年后仍有41%。
  • 对带状疱疹相关住院的保护在5至不足8年间从90%降至53%。

核心结论

  • 带状疱疹活疫苗初期有效,但疫苗有效性随时间显著下降,接种10年后对带状疱疹的保护较低,但对带状疱疹后神经痛的保护仍较高。

主要发现

  • 在1 505 647人中,507 444人(34%)接种了带状疱疹活疫苗;共75 135例带状疱疹病例,其中4982例(7%)发展为带状疱疹后神经痛,4439例(6%)发生带状疱疹眼病,556例(0.7%)因带状疱疹住院。
  • 对带状疱疹的疫苗有效性从接种后第一年的67%(95%CI 65%至69%)下降至10年后的15%(95%CI 5%至24%)。
  • 对带状疱疹后神经痛的疫苗有效性从第一年的83%(95%CI 78%至87%)下降至10年后的41%(95%CI 17%至59%)。
  • 对带状疱疹眼病的疫苗有效性在5至不足8年间从71%(95%CI 63%至76%)下降至29%(95%CI 18%至39%)。
  • 对带状疱疹住院的疫苗有效性在5至不足8年间从90%(95%CI 67%至97%)下降至53%(95%CI 25%至70%)。

关键数值与推荐

  • 全程随访期间,对带状疱疹的总体疫苗有效性为46%(95%CI 45%至47%),对带状疱疹后神经痛为62%(95%CI 59%至65%),对带状疱疹眼病为45%(95%CI 40%至49%),对带状疱疹住院为66%(95%CI 55%至74%)。

临床怎么用

  • 全科医生应知晓带状疱疹活疫苗初期保护力高但随时间下降,接种10年后对带状疱疹的保护较低,但对带状疱疹后神经痛仍有中等保护,可据此与老年患者讨论接种获益与时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effectiveness of live zoster vaccine during more than 10 years after vaccination; and to describe methods for ascertaining vaccine effectiveness in the context of waning. DESIGN: Real world cohort study using electronic health records. SETTING: Kaiser Permanente Northern California, an integrated healthcare delivery system in the US, 1 January 2007 to 31 December 2018. POPULATION: More than 1.5 million people aged 50 years and older followed for almost 9.4 million person years. MAIN OUTCOME MEASURE: Vaccine effectiveness in preventing herpes zoster, postherpetic neuralgia, herpes zoster ophthalmicus, and admission to hospital for herpes zoster was assessed. Change in vaccine effectiveness by time since vaccination was examined using Cox regression with a calendar timeline. Time varying indicators were specified for each interval of time since vaccination (30 days to less than one year, one to less than two years, etc) and adjusted for covariates. RESULTS: Of 1 505 647 people, 507 444 (34%) were vaccinated with live zoster vaccine. Among 75 135 incident herpes zoster cases, 4982 (7%) developed postherpetic neuralgia, 4439 (6%) had herpes zoster ophthalmicus, and 556 (0.7%) were admitted to hospital for herpes zoster. For each outcome, vaccine effectiveness was highest in the first year after vaccination and decreased substantially over time. Against herpes zoster, vaccine effectiveness waned from 67% (95% confidence interval 65% to 69%) in the first year to 15% (5% to 24%) after 10 years. Against postherpetic neuralgia, vaccine effectiveness waned from 83% (78% to 87%) to 41% (17% to 59%) after 10 years. Against herpes zoster ophthalmicus, vaccine effectiveness waned from 71% (63% to 76%) to 29% (18% to 39%) during five to less than eight years. Against admission to hospital for herpes zoster, vaccine effectiveness waned from 90% (67% to 97%) to 53% (25% to 70%) during five to less than eight years. Across all follow-up time, overall vaccine effectiveness was 46% (45% to 47%) against herpes zoster, 62% (59% to 65%) against postherpetic neuralgia, 45% (40% to 49%) against herpes zoster ophthalmicus, and 66% (55% to 74%) against admission to hospital for herpes zoster. CONCLUSIONS: Live zoster vaccine was effective initially. Vaccine effectiveness waned substantially yet some protection remained 10 years after vaccination. After 10 years, protection was low against herpes zoster but higher against postherpetic neuralgia. TRIAL REGISTRATION: ClinicalTrials.gov number NCT01600079; EU PAS register number EUPAS17502.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Klein NP, Bartlett J, Fireman B, et al. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. BMJ. 2023. PMID: 37940142. doi:10.1136/bmj-2023-076321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。